Torren Management’s Keros Therapeutics KROS Stock Holding History

Torren Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11	Closed	-$224	–	1226
2025 Q4	$224	Buy	+11	New	+$193	﹤0.01%	1406

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Torren Management's KROS Position: Q1 2026 in Review

Torren Management sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 11 shares — an estimated $224 sold.

Torren Management first reported a position in KROS in Q4 2025 and held it in 1 quarter. The position peaked at $224 in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Torren Management reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
Torren Management sold 11 Keros Therapeutics shares in Q1 2026, an estimated $224.
Torren Management first reported a position in Keros Therapeutics in Q4 2025 and held it in 1 quarter.
Torren Management's Keros Therapeutics position peaked at $224 in Q4 2025.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.